0001140361-24-029714.txt : 20240611 0001140361-24-029714.hdr.sgml : 20240611 20240611162810 ACCESSION NUMBER: 0001140361-24-029714 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240607 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NexImmune, Inc. CENTRAL INDEX KEY: 0001538210 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40045 FILM NUMBER: 241036165 BUSINESS ADDRESS: STREET 1: 9119 GAITHER ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-825-9810 MAIL ADDRESS: STREET 1: 9119 GAITHER ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 8-K 1 ny20030506x2_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2024


NEXIMMUNE, INC.
(Exact name of registrant as specified in its charter)


Delaware
001-40045
45-2518457
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

9119 Gaither Road
  
Gaithersburg, Maryland
20877
(Address of principal executive offices)
(zip code)

Registrant’s telephone number, including area code: (301) 825-9810


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share
  
NEXI
  
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02 Unregistered Sales of Equity Securities

The disclosure required by this Item is included in Item 5.03 of this Current Report on Form 8-K and is incorporated herein by reference. The issuance and sale of one share of the Series A Preferred Stock for consideration of $0.01 was exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.

Item 3.03 Material Modifications to Rights of Security Holders

The disclosure required by this Item is included in Item 5.03 of this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Bylaws Amendment

On June 7, 2024, the Board of Directors (the “Board”) of NexImmune, Inc. (the “Company”) approved an amendment (the “Bylaws Amendment”) to the Company’s Amended and Restated Bylaws. The Bylaw Amendment states that, at all meetings of the stockholders, one-third of the voting power of all shares of capital stock entitled to vote (or deemed entitled to vote) shall constitute a quorum. The Bylaw Amendment became effective on June 7, 2024.

Series A Preferred Stock

On June 11, 2024, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of the State of Delaware designating, effective as of the time of filing, and containing the rights, preferences, privileges and restrictions of one share of Series A Preferred Stock. The Certificate of Designation provides that if the aggregate number of shares of common stock, par value $0.0001 per share (“Common Stock”), present in person or by proxy and entitled to vote thereon that voted “for” a Voting Proposal (as defined below) is greater than the aggregate number of shares of Common Stock present in person or by proxy and entitled to vote thereon that voted “against” or “abstain” on such Voting Proposal, then the share of Series A Preferred Stock will have a number of votes equal to the number of outstanding shares of the Common Stock, on the record date for determining stockholders entitled to vote, and will vote together with the outstanding shares of Common Stock as a single class exclusively with respect to (i) any proposal to approve the liquidation and dissolution of the Company and any related plan of liquidation and dissolution (the “Dissolution Proposal”), (ii) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Dissolution Proposal, or (iii) any other matter the Board determines (in its sole discretion) is related to the Dissolution Proposal (each, a Voting Proposal”). The Series A Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware.

The Series A Preferred Stock is not convertible into shares of Common Stock or any other class or series of stock of the Company. In the event of any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holder of the share of Series A Preferred Stock shall be entitled to receive $0.01, payable in cash out of funds legally available. The holder of the share of Series A Preferred Stock will not be entitled to receive dividends of any kind.

Unless prohibited by Delaware law by virtue of a lack of sufficient surplus, legally available funds or otherwise and subject to the fiduciary duties of the Board of Directors of the Company, the outstanding share of Series A Preferred Stock may be redeemed at any time upon the order of the Board of Directors in its sole discretion. Upon such redemption, the holder of the share of Series A Preferred Stock will receive consideration of $0.01 in cash.

The foregoing summaries of the Bylaw Amendment and Certificate of Designation do not purport to be complete and are subject to, and qualified in their entirety by, such documents, which are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 9.01.          Financial Statements and Exhibits.

(d)          Exhibits.

Exhibit
No.
  
Description
 
Amendment to the Amended and Restated Bylaws of NexImmune, Inc.
 
Certificate of Designation of Series A Preferred Stock dated June 11, 2024.
104
  
Cover Page Interactive Data File (Embedded within the Inline XBRL Document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
NEXIMMUNE, INC.
     
 
By:
/s/ Kristi Jones
   
Kristi Jones
   
Chief Executive Officer

Date: June 11, 2024
 EX-3.1 2 ny20030506x2_ex3-1.htm EXHIBIT 3.1
Exhibit 3.1

AMENDMENT
TO THE AMENDED AND RESTATED BYLAWS OF
NEXIMMUNE, INC.

This Amendment (this “Amendment”) to the Amended and Restated Bylaws (the “Bylaws”) of NexImmune, Inc., a Delaware corporation (the “Company”), is effective as of June 7, 2024 and is made pursuant to Article Seventh of the Sixth Amended and Restated Certificate of Incorporation, as amended, of the Company.


 1.
Section 4 of Article I of the Bylaws is hereby amended by deleting Section 4 of Article I of the Bylaws in its entirety and replacing it with the following:

At any meeting of the stockholders, the holders of one-third of the voting power of all of the shares of capital stock entitled to vote (or deemed entitled to vote) at the meeting, present in person or represented by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law or by rules of any stock exchange upon which the Corporation’s securities are listed. Where a separate vote by a class or classes is required, one third of the voting power of the shares of such class or classes, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter.

If a quorum shall fail to attend any meeting, the chairman of the meeting may adjourn the meeting to another place, if any, date, or time.


 2.
Except as set forth in this Amendment, no terms or conditions of the Bylaws have changed.  In the event of any inconsistencies between the terms of this Amendment and the Bylaws, the terms of this Amendment shall prevail.

EX-3.2 3 ny20030506x2_ex3-2.htm EXHIBIT 3.2
Exhibit 3.2

CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF NEXIMMUNE, INC.

NexImmune, Inc., a Delaware corporation (“Company”), does hereby certify that the Board of Directors of the Company (“Board”) adopted the following resolution:

RESOLVED, pursuant to authority conferred by the Sixth Amended and Restated Certificate of Incorporation of the Company, the Board designates, creates and authorizes a series of preferred stock, par value $0.0001 per share, with the powers (including voting powers), designations, preferences and relative, participating, optional and other special rights, and qualifications, limitations, and restrictions thereof, as follows.

1.
Number and Designation.  There is one authorized share of this series, designated “Series A Preferred Stock”.

2.
Voting.  Except as provided in this Section 2 or required by law, the Series A Preferred Stock shall not entitle the holder thereof, as such, to vote on any matter.  At any meeting of stockholders at which any Voting Proposal is submitted to a vote (“Voting Proposal Meeting”), if the aggregate number of shares of common stock, par value $0.0001 per share (“Common Stock”), present in person or by proxy and entitled to vote thereon that voted “for” such Voting Proposal is greater than the aggregate number of shares of Common Stock present in person or by proxy and entitled to vote thereon that voted “against” or “abstain” on such Voting Proposal, then the Series A Preferred Stock shall entitle the holder thereof, as such, to (i) vote together with the holders of Common Stock as a single class on such Voting Proposal and (ii) cast a number of votes, in person or by proxy, on such Voting Proposal equal to the number of shares of Common Stock outstanding on the record date for determining stockholders entitled to vote on such Voting Proposal (such number of votes, the “Votes”); provided, however, that, notwithstanding anything to the contrary herein, for purposes of determining the existence of a quorum at a Voting Proposal Meeting, the Series A Preferred Stock shall be deemed to entitle the holder thereof, as such, to have the voting power that is equal to the Votes.  For this purpose, “Voting Proposal” means a proposal to approve (i) the liquidation and dissolution of the Company and any related plan of liquidation and dissolution (“Dissolution Proposal”), (ii) an adjournment of any meeting at which a Dissolution Proposal is presented to stockholders, or (iii) any other matter the Board determines (in its sole discretion) is related to a Dissolution Proposal.

3.
Liquidation Preference.  Upon the liquidation, dissolution or winding up of the Company, the Series A Preferred Stock shall entitle the holder thereof, as such, to receive $0.01, payable in cash out of funds legally available therefor, by reason of its ownership thereof, which shall be paid prior to the payment of any amounts to the holders of Common Stock in connection with such liquidation, dissolution or winding up, and no more.  Any series of preferred stock authorized and issued by the Company following the effectiveness of this Certificate of Designation may rank senior or junior to, or on parity with, the Series A Preferred Stock, as determined by the terms of such series of preferred stock.


4.
Dividends.  No dividends shall be paid on the Series A Preferred Stock.

5.
Redemption.  The Series A Preferred Stock may be redeemed at any time at the option of the Board (in its sole discretion) for $0.01, payable in cash and only out of funds legally available therefor.

6.
Merger or Consolidation.  In the event of a merger or consolidation of the Company with or into another entity (whether or not the Company is the surviving entity), the holder of Series A Preferred Stock shall not be entitled to receive any consideration in respect thereof.

7.
Uncertificated.  The Series A Preferred Stock shall be uncertificated.

8.
Transfer Restriction.  The holder of the Series A Preferred Stock shall not, directly or indirectly, transfer (by sale, assignment, encumbrance, hypothecation, pledge, conveyance in trust, gift, bequest, devise or descent, by operation of law or by any other transfer or disposition of any kind, including to any receivers, creditors, trustees in bankruptcy or other insolvency proceeding) such share to any other person or entity without the prior written consent of the Board (acting in its sole discretion); provided that this sentence shall not prohibit the grant or delivery of a proxy to any person designated or appointed by the Company to act on behalf of the holders of the Company’s capital stock who have so granted a proxy in connection with any Voting Proposal.  A purported transfer in violation of this Section 8 shall be null and void ab initio.

9.
Amendments.  In addition to any vote required by law, any amendment to the provisions of this Certificate of Designation shall require the approval of the holder of the Series A Preferred Stock, voting as a separate class.

* * * * *

In Witness Whereof, the undersigned has caused this Certificate to be signed by a duly authorized officer on the date set forth below.

 
NEXIMMUNE, INC.
     
     
 
By:
/s/ Kristi Jones
 
Name:
Kristi Jones
 
Title:
Chief Executive Officer
     
 
Dated: June 11, 2024

EX-101.SCH 4 nexi-20240607.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 nexi-20240607_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 nexi-20240607_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2024
Current Fiscal Year End Date --12-31
Entity File Number 001-40045
Entity Registrant Name NexImmune, Inc.
Entity Central Index Key 0001538210
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2518457
Entity Address, Address Line One 9119 Gaither Road
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20877
City Area Code 301
Local Phone Number 825-9810
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol NEXI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://neximmune.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName - ny20030506x2_8k.htm 11 nexi-20240607.xsd nexi-20240607_lab.xml nexi-20240607_pre.xml ny20030506x2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ny20030506x2_8k.htm": { "nsprefix": "nexi", "nsuri": "http://neximmune.com/20240607", "dts": { "schema": { "local": [ "nexi-20240607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "nexi-20240607_lab.xml" ] }, "presentationLink": { "local": [ "nexi-20240607_pre.xml" ] }, "inline": { "local": [ "ny20030506x2_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://neximmune.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240607to20240607", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ny20030506x2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240607to20240607", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ny20030506x2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://neximmune.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001140361-24-029714-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-029714-xbrl.zip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end XML 19 ny20030506x2_8k_htm.xml IDEA: XBRL DOCUMENT 0001538210 2024-06-07 2024-06-07 false --12-31 NexImmune, Inc. 0001538210 NASDAQ 8-K 2024-06-07 DE 001-40045 45-2518457 9119 Gaither Road Gaithersburg MD 20877 301 825-9810 false false false false Common Stock, $0.0001 par value per share NEXI true false